Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 2
1972 2
1975 1
1976 3
1977 1
1978 3
1979 1
1980 3
1981 2
1982 3
1983 3
1984 5
1985 5
1986 6
1987 5
1988 3
1989 3
1990 7
1991 8
1992 6
1993 7
1994 4
1995 11
1996 12
1997 10
1998 12
1999 6
2000 15
2001 28
2002 21
2003 10
2004 20
2005 11
2006 12
2007 11
2008 12
2009 12
2010 22
2011 37
2012 46
2013 51
2014 41
2015 18
2016 39
2017 40
2018 26
2019 42
2020 31
2021 49
2022 62
2023 69
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

807 results

Results by year

Filters applied: . Clear all
Page 1
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
Born E, Lipskaia L, Breau M, Houssaini A, Beaulieu D, Marcos E, Pierre R, Do Cruzeiro M, Lefevre M, Derumeaux G, Bulavin DV, Delcroix M, Quarck R, Reen V, Gil J, Bernard D, Flaman JM, Adnot S, Abid S. Born E, et al. Circulation. 2023 Feb 21;147(8):650-666. doi: 10.1161/CIRCULATIONAHA.122.058794. Epub 2022 Dec 14. Circulation. 2023. PMID: 36515093
BACKGROUND: Senescent cells (SCs) are involved in proliferative disorders, but their role in pulmonary hypertension remains undefined. We investigated SCs in patients with pulmonary arterial hypertension and the role of SCs in animal pulmonary …
BACKGROUND: Senescent cells (SCs) are involved in proliferative disorders, but their role in pulmonary hypertension remains un …
Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA.
Shu T, Zhang J, Zhou Y, Chen Z, Li J, Tang Q, Lei W, Xing Y, Wang J, Wang C. Shu T, et al. Eur Respir J. 2023 Mar 2;61(3):2200582. doi: 10.1183/13993003.00582-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36423907 Free PMC article.
BACKGROUND: Pulmonary hypertension (PH) is a life-threatening disease featuring pulmonary vessel remodelling and perivascular inflammation. ...METHODS: EOS infiltration and chemotaxis were investigated in peripheral blood and lung tissues from pulmonary …
BACKGROUND: Pulmonary hypertension (PH) is a life-threatening disease featuring pulmonary vessel remodelling and periva …
The physiological basis of pulmonary arterial hypertension.
Naeije R, Richter MJ, Rubin LJ. Naeije R, et al. Eur Respir J. 2022 Jun 16;59(6):2102334. doi: 10.1183/13993003.02334-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34737219 Free PMC article. Review.
Pulmonary arterial hypertension (PAH) is a rare dyspnoea-fatigue syndrome caused by a progressive increase in pulmonary vascular resistance and eventual right ventricular (RV) failure. In spite of extensive pulmonary vascular remodelling, lung function …
Pulmonary arterial hypertension (PAH) is a rare dyspnoea-fatigue syndrome caused by a progressive increase in pulmonary …
SOX17 Deficiency Mediates Pulmonary Hypertension: At the Crossroads of Sex, Metabolism, and Genetics.
Sangam S, Sun X, Schwantes-An TH, Yegambaram M, Lu Q, Shi Y, Cook T, Fisher A, Frump AL, Coleman A, Sun Y, Liang S, Crawford H, Lutz KA, Maun AD, Pauciulo MW, Karnes JH, Chaudhary KR, Stewart DJ, Langlais PR, Jain M, Alotaibi M, Lahm T, Jin Y, Gu H, Tang H, Nichols WC, Black SM, Desai AA. Sangam S, et al. Am J Respir Crit Care Med. 2023 Apr 15;207(8):1055-1069. doi: 10.1164/rccm.202203-0450OC. Am J Respir Crit Care Med. 2023. PMID: 36913491 Free PMC article.
Rationale: Genetic studies suggest that SOX17 (SRY-related HMG-box 17) deficiency increases pulmonary arterial hypertension (PAH) risk. Objectives: On the basis of pathological roles of estrogen and HIF2alpha (hypoxia-inducible factor 2alpha) signaling in …
Rationale: Genetic studies suggest that SOX17 (SRY-related HMG-box 17) deficiency increases pulmonary arterial hypertension (P …
RAB7 deficiency impairs pulmonary artery endothelial function and promotes pulmonary hypertension.
Piper B, Bogamuwa S, Hossain T, Farkas D, Rosas L, Green AC, Newcomb G, Sun N, Ovando-Ricardez JA, Horowitz JC, Bhagwani AR, Yang H, Kudryashova TV, Rojas M, Mora AL, Yan P, Mallampalli RK, Goncharova EA, Eckmann DM, Farkas L. Piper B, et al. J Clin Invest. 2024 Feb 1;134(3):e169441. doi: 10.1172/JCI169441. J Clin Invest. 2024. PMID: 38015641 Free PMC article.
Pulmonary arterial hypertension (PAH) is a devastating and progressive disease with limited treatment options. ...We found reduced expression of RAB7 in ECs from patients with PAH. Endothelial haploinsufficiency of RAB7 caused spontaneous pulmonary hyperte …
Pulmonary arterial hypertension (PAH) is a devastating and progressive disease with limited treatment options. ...We found red …
Macrophage-NLRP3 Activation Promotes Right Ventricle Failure in Pulmonary Arterial Hypertension.
Al-Qazazi R, Lima PDA, Prisco SZ, Potus F, Dasgupta A, Chen KH, Tian L, Bentley RET, Mewburn J, Martin AY, Wu D, Jones O, Maurice DH, Bonnet S, Provencher S, Prins KW, Archer SL. Al-Qazazi R, et al. Am J Respir Crit Care Med. 2022 Sep 1;206(5):608-624. doi: 10.1164/rccm.202110-2274OC. Am J Respir Crit Care Med. 2022. PMID: 35699679 Free PMC article.
Rationale: Pulmonary arterial hypertension (PAH) often results in death from right ventricular failure (RVF). ...Methods: Rats with decompensated RV hypertrophy (monocrotaline [MCT] and Sugen-5416 hypoxia [SuHx]) were compared with compensated RV hypertrophy …
Rationale: Pulmonary arterial hypertension (PAH) often results in death from right ventricular failure (RVF). ...Methods: Rats …
SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension.
Walters R, Vasilaki E, Aman J, Chen CN, Wu Y, Liang OD, Ashek A, Dubois O, Zhao L, Sabrin F, Cebola I, Ferrer J, Morrell NW, Klinger JR, Wilkins MR, Zhao L, Rhodes CJ. Walters R, et al. Circulation. 2023 May 23;147(21):1606-1621. doi: 10.1161/CIRCULATIONAHA.122.061940. Epub 2023 Apr 17. Circulation. 2023. PMID: 37066790 Free PMC article.
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease characterized by remodeling of the pulmonary arteries, increased vascular resistance, and right-sided heart failure. ...SOX17 enhancer knockout in mice reduced lung SOX17 expression, resultin …
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease characterized by remodeling of the pulmonary arteri …
Obstructive sleep apnoea syndrome.
Lévy P, Kohler M, McNicholas WT, Barbé F, McEvoy RD, Somers VK, Lavie L, Pépin JL. Lévy P, et al. Nat Rev Dis Primers. 2015 Jun 25;1:15015. doi: 10.1038/nrdp.2015.15. Nat Rev Dis Primers. 2015. PMID: 27188535 Review.
OSAS is also associated with cardiovascular co-morbidities, including hypertension, arrhythmias, stroke, coronary heart disease, atherosclerosis and overall increased cardiovascular mortality, as well as metabolic dysfunction. Whether treating sleep apnoea can fully revers …
OSAS is also associated with cardiovascular co-morbidities, including hypertension, arrhythmias, stroke, coronary heart disease, athe …
Single-cell RNA sequencing profiling of mouse endothelial cells in response to pulmonary arterial hypertension.
Rodor J, Chen SH, Scanlon JP, Monteiro JP, Caudrillier A, Sweta S, Stewart KR, Shmakova A, Dobie R, Henderson BEP, Stewart K, Hadoke PWF, Southwood M, Moore SD, Upton PD, Morrell NW, Li Z, Chan SY, Handen A, Lafyatis R, de Rooij LPMH, Henderson NC, Carmeliet P, Spiroski AM, Brittan M, Baker AH. Rodor J, et al. Cardiovasc Res. 2022 Aug 24;118(11):2519-2534. doi: 10.1093/cvr/cvab296. Cardiovasc Res. 2022. PMID: 34528097 Free PMC article.
AIMS: Endothelial cell (EC) dysfunction drives the initiation and pathogenesis of pulmonary arterial hypertension (PAH). We aimed to characterize EC dynamics in PAH at single-cell resolution. METHODS AND RESULTS: We carried out single-cell RNA sequencing (scRNA-seq) …
AIMS: Endothelial cell (EC) dysfunction drives the initiation and pathogenesis of pulmonary arterial hypertension (PAH). We ai …
Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.
Joshi SR, Liu J, Bloom T, Karaca Atabay E, Kuo TH, Lee M, Belcheva E, Spaits M, Grenha R, Maguire MC, Frost JL, Wang K, Briscoe SD, Alexander MJ, Herrin BR, Castonguay R, Pearsall RS, Andre P, Yu PB, Kumar R, Li G. Joshi SR, et al. Sci Rep. 2022 May 12;12(1):7803. doi: 10.1038/s41598-022-11435-x. Sci Rep. 2022. PMID: 35551212 Free PMC article.
Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein that improves cardiopulmonary function in patients with pulmonary arterial hypertension (PAH) by selectively trapping activins and growth differentiation factors. ...Therapeutic treatment wit …
Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein that improves cardiopulmonary function in patients with pulmon …
807 results